Nan Wang

220 posts

Nan Wang banner
Nan Wang

Nan Wang

@nwang_epi

Katılım Ocak 2022
52 Takip Edilen22 Takipçiler
Nan Wang retweetledi
Wei Lab@wisc
Wei Lab@wisc@Wei_Lab_WISC·
Excited to be part of the first Chicago Chemical Biology and Therapeutics Symposium!!
Wei Lab@wisc tweet media
English
0
2
21
1.3K
Nan Wang
Nan Wang@nwang_epi·
Congratulations to Wei and the entire team on this exciting manuscript from the lab! A wonderful example of collaborative science uncovering new biology of mammalian metabolism
Wei Lab@wisc@Wei_Lab_WISC

Excited to share the first manuscript from our lab! Here we identified a shared enzymatic mechanism linking N-acetylated β-amino acids to energy balance regulation @jbiolchem. Congratulations to our first PhD student, Ruida Li, from @CMB_UWMadison, for leading this work. Grateful for the tremendous support from @JudithSimcox @UWBiochem @longlabstanford @ssiipei jbc.org/article/S0021-…

English
0
0
0
40
Nan Wang retweetledi
Wei Lab@wisc
Wei Lab@wisc@Wei_Lab_WISC·
My lab is recruiting a postdoc fellow to characterize new biochemical pathways that control taurine and glucose metabolism. Email me at wei.wei2@wisc.edu to apply! Please help RT🙏 @longlabstanford @JudithSimcox @UWBiochem
English
6
122
293
38.5K
Wei Lab@wisc
Wei Lab@wisc@Wei_Lab_WISC·
I'm beyond thrilled to announce that I will be joining the Biochemistry Department at the University of Wisconsin–Madison this fall as an Assistant Professor. My lab will focus on deorphanizing biochemical pathways that regulate nutrient metabolism @UWBiochem @uwmadisonipib
English
72
21
471
57.8K
Nan Wang retweetledi
Ziyad Al-Aly, MD
Ziyad Al-Aly, MD@zalaly·
GLP-1 drugs are revolutionizing the way we think about obesity. It is a chronic disease (like high blood pressure), and might actually be a form of food addiction. One reason these drugs are so effective in treating obesity could be that they address the underlying addiction. We and others have shown that GLP-1 drugs reduce risks of many substance use and addiction disorders. buff.ly/4jm6iqC
English
0
8
58
6.5K
Nan Wang retweetledi
Ziyad Al-Aly, MD
Ziyad Al-Aly, MD@zalaly·
New Long Covid policy paper from Norway outlines knowledge gaps and lessons learnt for developing preparedness for future pandemics. Section 5 (pictured below) outlines their recommendations. Led by Sara Illman, PhD and colleagues. nordforsk.org/2025/knowledge…
Ziyad Al-Aly, MD tweet media
English
3
79
208
13.8K
Nan Wang retweetledi
Ziyad Al-Aly, MD
Ziyad Al-Aly, MD@zalaly·
Thanks to @DKThomp for hosting me on his podcast. We talked about the GLP-1 and more. Details in this post below.
Derek Thompson@DKThomp

New ep: Are GLP-1s "the greatest medical breakthrough of the 21st century"? A new study of 2m Veterans Affairs patients with diabetes found GLP1 use was associated with a reduced risk of: - substance use disorders - psychotic disorders - Alzheimer's and dementia - clotting and heart attacks - infectious illnesses - several respiratory conditions To be blunt: WTAF is going on here? How did we turn synthesized Gila monster spit into a drug that seems to control diabetes, promote weight loss, and have such a absurdly wide range of positive effectiveness? Today we speak with @zalaly, an author of the new paper. What did his research look at? Why should we trust it? Where was the strongest signal? What new risks did we uncover? How on earth can a single drug do all of this? And how is it teaching us more deeply about "pleiotropic" medicine—single drugs that have a zillion unrelated positive side effects—and even the nature of willpower and free will in health? open.spotify.com/episode/0UtT3D…

English
0
3
26
4.1K
Nan Wang retweetledi
Ziyad Al-Aly, MD
Ziyad Al-Aly, MD@zalaly·
🚨 ICYMI: Our latest study shows that the popular GLP-1 weight loss drugs (e.g. Ozempic) have broad health benefits — reducing risks of 42 health conditions. They are not without risks — increasing risks of of 19 health conditions. nature.com/articles/s4159…
English
0
14
42
3K
Nan Wang retweetledi
Ziyad Al-Aly, MD
Ziyad Al-Aly, MD@zalaly·
🚨 New from my team: In a study of over 2 million people, we comprehensively mapped the benefits and risks of GLP-1 (weight loss drugs) across 175 health conditions. 📄 Free access to the full study: rdcu.be/d6VYU 🧵 Explore the key findings: x.com/zalaly/status/…
Ziyad Al-Aly, MD@zalaly

1. What are the benefits and risks of GLP1? Our new study in @naturemedicine comprehensively maps all the benefits and risks of GLP-1 receptor agonists (GLP-1) (Ozempic, Wegovy, Mounjaro, Zepbound). By @Biostayan, Taeyoung Choi and me 🧵 nature.com/articles/s4159…

English
7
30
146
13.4K
Nan Wang retweetledi
Ziyad Al-Aly, MD
Ziyad Al-Aly, MD@zalaly·
Let me address this. We wrote the grant to do this project in 2018. It was funded in 2020. We deliberately delayed this to devote time and effort to addressing Covid and Long Covid. My team and I remain committed to working on LC, but we cannot default on our other commitments.
@[email protected]@augieray

@zalaly @NatureMedicine @Biostayan I must admit, I'm disappointed the most trusted voice in Long COVID research has dedicated time to non-COVID study. There must be enough researchers around who can study GLP-1. Meanwhile, LC sufferers need solutions and most people are ignoring the risks of COVID reinfections.

English
23
30
513
26.5K

Keşfet

@jbiolchem @CMB_UWMadison @JudithSimcox @UWBiochem @longlabstanford @ssiipei @Wei_Lab_WISC @SvenssonLab